Cargando…
Weekly low-dose methotrexate for reduction of Global Initiative for Asthma Step 5 treatment in severe refractory asthma: study protocol for a randomized controlled trial
BACKGROUND: Patients with chronic severe asthma (CSA) have a crippling disease and current available treatments are not satisfactory. Thus, management of CSA remains a major unmet need. Although the evidence from existing randomized controlled trials fails to support a definite role for immunomodula...
Autores principales: | Polosa, Riccardo, Bellinvia, Salvatore, Caruso, Massimo, Emma, Rosalia, Alamo, Angela, Kowalski, Marek Leszek, Domingo, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302097/ https://www.ncbi.nlm.nih.gov/pubmed/25523634 http://dx.doi.org/10.1186/1745-6215-15-492 |
Ejemplares similares
-
Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Emma, Rosalia, et al.
Publicado: (2018) -
Recommendation for optimal management of severe refractory asthma
por: Morjaria, Jaymin B, et al.
Publicado: (2010) -
The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma
por: Bilocca, David, et al.
Publicado: (2017) -
Methotrexate as an oral corticosteroid-sparing agent in severe asthma: the emergence of a responder asthma endotype
por: Knarborg, Malene, et al.
Publicado: (2014) -
Next steps in precision approaches for asthma-proteomics and asthma endotypes
por: Brasier, Allan R.
Publicado: (2022)